Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The session is scheduled for September 16 at 8:30 a.m. EDT and will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website.
The conference appearance comes as Helus Pharma, the commercial operating name of Cybin Inc., advances its pipeline of proprietary novel serotonergic agonists (NSAs). These synthetic molecules are designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering new avenues for treating depression, anxiety, and other mental health conditions.
Helus Pharma’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The company’s participation in a major healthcare investor conference underscores the growing interest in psychedelic-inspired treatments for mental health. With class-leading data, Helus Pharma aims to improve the treatment landscape by providing durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For investors, the fireside chat offers an opportunity to gain insights into Helus Pharma’s strategic direction and clinical progress. The full press release can be accessed at https://ibn.fm/r0jfC. For ongoing updates, the company’s newsroom is available at https://ibn.fm/HELP.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, disseminated the announcement. BioMedWire is part of the Dynamic Brand Portfolio@IBN, which provides wire solutions, article syndication, press release enhancement, social media distribution, and tailored corporate communications. More information is available at https://www.BioMedWire.com, and terms of use and disclaimers can be found at https://www.BioMedWire.com/Disclaimer.
The presentation at the Morgan Stanley conference could raise Helus Pharma’s profile among institutional investors and potentially attract additional investment as it continues late-stage development of its mental health treatments. With Breakthrough Therapy Designation for HLP003, the company is positioned to potentially address significant unmet needs in major depressive disorder and generalized anxiety disorder.
